Work

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a KRAS-Targeted Combination Therapy in Metastatic Pancreatic Adenocarcinoma

Year: 2026
Type: article
Abstract: The annual report required under 21 C.F.R. 312.33 is a short document with a long list of contributors: clinical operations, pharmacovigilance, nonclinical development, chemistry, manufacturing, and controls, quality, and regulatory publishing all supply content that must reconcile to the same data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND in which an oral KRAS-pathway inhibitor is combined with a standard multi-agent chemotherapy backbone as first-line treatment of metastatic pancreatic adenocarcinoma. It sets out the reporting period and deadline, study accounting (56 of 80 planned participants entered), the content required by each paragraph of the regulation, placement of every component in Module 1.13 of the eCTD, Form FDA 1571 entries, a draft cover letter, and an 11-step timeline. It corrects a common error, placement of the report in Module 1.3, and closes with recommendations for regulatory operations teams.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236735347
FWCI:
Cites:
Cited by:
Related to: 10